ABL Bio
Korea - SeongnamBiotechnology
Focus: ABL Bio is an early-stage Korean biotechnology company founded in 2020, specializing in antibody-based immuno-oncology therapeutics targeting advanced solid tumors. The company operates at pre-clinical and Phase 1 stage with a focused pipeline and minimal public presence.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Open Jobs
1-2 this month
Stable — net -2 jobs in 30d
0 added, 2 removed. Backfill posture.
Should You Work at ABL Bio?
AI assessmentABL Bio is a high-risk, high-upside early-stage play suited only for scientists and operators comfortable with pre-revenue biotech uncertainty and seeking hands-on pipeline development experience.
Why Work Here
- Ground-floor opportunity to shape a pipeline of 5 Phase 1 antibody programs in high-value oncology before institutional scaling
- Exposure to antibody engineering and immuno-oncology modalities in an emerging market (South Korea biotech sector)
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ABL001
Advanced Solid TumorsClinical Trials (2)
NCT04492033A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients
Phase 1/2Help build intelligence for ABL Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.